Cautionary Note Regarding Forward-Looking Statements

This letter contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements by Eagle Pharmaceuticals, Inc. (“Eagle”) regarding its development of RYANODEX® as a possible therapeutic option for COVID-19 including the potential benefits, antiviral activity and efficacy of RYANODEX®; Eagle’s ability to replicate in vitro laboratory tests of RYANODEX® in future clinical trial and in vivo results; the initiation, progress and development of RYANODEX® in a clinical trial of patients with COVID-19; and the ability to protect employee safety and minimize business disruption in light of the COVID-19 pandemic. All statements that are not statements of historical facts are forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks that results from in vitro laboratory tests of RYANODEX® are not necessarily predictive of future clinical trial and in vivo results; Eagle may not fully enroll the clinical trial of RYANODEX® or it will take longer than expected; uncertainty of success in the development and potential commercialization of RYANODEX® as a therapy for COVID-19; unexpected concerns that may arise from additional data, analysis or results obtained during the clinical trial; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of RYANODEX® as a therapy for COVID-19; the occurrence of adverse safety events; risks of unexpected costs or delays; the risks of other unexpected hurdles; product liability claims; third party collaboration risks; and the impact related to the effect of COVID-19 or other public health epidemics on Eagle’s sales and operations, including employees. Forward-looking statements in this letter should be evaluated together with the many risks and uncertainties that affect Eagle’s business, particularly those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 2, 2020 and its other subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this letter speak only as of the date on which they were made. Except to the extent required by law, Eagle undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.